Abstract
Small molecule kinase inhibitors are important tools for studying cellular signaling pathways, phenotypes and are, occasionally, useful clinical agents. With stereochemistry pervasive throughout the molecules of life it is no surprise that a single stereocenter can bestow a ligand with distinct binding affinities to various protein targets. While the majority of small molecule kinase inhibitors reported to date are achiral, a number of asymmetric compounds show great utility as tools for probing kinase-associated biomolecular events as well as promising therapeutic leads. The mechanism by which chirality is introduced varies but includes screening of chiral libraries, incorporation of chiral centers during optimization efforts and the rational installation of a chiral moiety as guided by structural and modeling efforts. Here we discuss several advanced chiral small molecule kinase inhibitors where stereochemistry plays an important role in terms of potency and selectivity.
Keywords: Kinase inhibitors, chirality, P38a, AKT, Erk, Jak3, TrkA, optically active, cellular signaling pathways, stereocenter, chiral libraries, chronic myelogenous leukemia, obstructive pulmonary disease COPD, rheumatoid arthritis, Crohn's disease
Current Topics in Medicinal Chemistry
Title: Chiral Kinase Inhibitors
Volume: 11 Issue: 7
Author(s): Jian-kang Jiang, Min Shen, Craig J. Thomas and Mathew B. Boxer
Affiliation:
Keywords: Kinase inhibitors, chirality, P38a, AKT, Erk, Jak3, TrkA, optically active, cellular signaling pathways, stereocenter, chiral libraries, chronic myelogenous leukemia, obstructive pulmonary disease COPD, rheumatoid arthritis, Crohn's disease
Abstract: Small molecule kinase inhibitors are important tools for studying cellular signaling pathways, phenotypes and are, occasionally, useful clinical agents. With stereochemistry pervasive throughout the molecules of life it is no surprise that a single stereocenter can bestow a ligand with distinct binding affinities to various protein targets. While the majority of small molecule kinase inhibitors reported to date are achiral, a number of asymmetric compounds show great utility as tools for probing kinase-associated biomolecular events as well as promising therapeutic leads. The mechanism by which chirality is introduced varies but includes screening of chiral libraries, incorporation of chiral centers during optimization efforts and the rational installation of a chiral moiety as guided by structural and modeling efforts. Here we discuss several advanced chiral small molecule kinase inhibitors where stereochemistry plays an important role in terms of potency and selectivity.
Export Options
About this article
Cite this article as:
Jiang Jian-kang, Shen Min, J. Thomas Craig and B. Boxer Mathew, Chiral Kinase Inhibitors, Current Topics in Medicinal Chemistry 2011; 11 (7) . https://dx.doi.org/10.2174/156802611795165052
DOI https://dx.doi.org/10.2174/156802611795165052 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Snake Venom Phospholipases A2: A Novel Tool Against Bacterial Diseases
Current Medicinal Chemistry Which Drugs for the Control of Fever in Critical Patients
Current Drug Targets Novel Insight into the Inflammatory and Cellular Responses Following Experimental Glaucoma Surgery: A Roadmap for Inhibiting Fibrosis
Current Molecular Medicine Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Molecular Basis of Mineralocorticoid Receptor Action in the Nervous System
CNS & Neurological Disorders - Drug Targets Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective
Current Neuropharmacology Beta-Blockers in Pediatric Hypertrophic Cardiomyopathies
Reviews on Recent Clinical Trials Biochemical and Structural Investigations of Bothropstoxin-II, a Myotoxic Asp49 Phospholipase A2 from Bothrops jararacussu Venom
Protein & Peptide Letters An Update on Drug Interactions with the Herbal Medicine Ginkgo biloba
Current Drug Metabolism Physiological Significance and Therapeutic Potential of Adrenomedullin in Pulmonary Hypertension
Cardiovascular & Hematological Disorders-Drug Targets Anti-Endotoxin Agents. 3. Rapid Identification of High-Affinity Lipopolysaccharide-Binding Compounds in a Substituted Polyamine Library
Combinatorial Chemistry & High Throughput Screening The Management and Outcomes of Pharmacological Treatments for Tinnitus
Current Neuropharmacology Editorial: Limited Utility of the Handgrip Test for the Diagnosis of Diabetic Cardiovascular Autonomic Neuropathy: “There’s Time Enough, But None to Spare”
Current Vascular Pharmacology Role of Vascular Endothelial Growth Factor in Kidney Disease
Current Vascular Pharmacology Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry Cannabinoids as Neuroprotective Agents in Traumatic Brain Injury
Current Pharmaceutical Design Renal and Urological Diseases of the Newborn Neonatal Acute Kidney Injury
Current Pediatric Reviews Carotid Artery Stenting for the Prevention of Thromboembolic Stroke
Vascular Disease Prevention (Discontinued) New Targets of Therapy in T-Cell Lymphomas
Current Drug Targets Mitochondria-Targeted Antioxidant Peptides
Current Pharmaceutical Design